FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Toru Kanke

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Concepts & Ideas

Disorders

Hyperalgesia

Co-author Network

Publications

TOP 3
Fui Goon Goh; Pei Yuen Ng; Mary Nilsson; Toru Kanke; Robin Plevin
Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling.
Toru Kanke; Mototsugu Kabeya; Satoko Kubo; S Kondo; K Yasuoka; J Tagashira; H Ishiwata; Masako Saka; T Furuyama; T Nishiyama; T Doi; Yukio Hattori; Atsufumi Kawabata; M R Cunningham; Robin Plevin
Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo.
E Ritchie; Masako Saka; Christopher MacKenzie; Robert M Drummond; C Wheeler-Jones; Toru Kanke; Robin Plevin
Cytokine upregulation of proteinase-activated-receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Toru Kanke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Fui Goon Goh; Pei Yuen Ng; Mary Nilsson; Toru Kanke; Robin Plevin
Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling.
British journal of pharmacology 2009;158(7):1695-704.
2009: Toru Kanke; Mototsugu Kabeya; Satoko Kubo; S Kondo; K Yasuoka; J Tagashira; H Ishiwata; Masako Saka; T Furuyama; T Nishiyama; T Doi; Yukio Hattori; Atsufumi Kawabata; M R Cunningham; Robin Plevin
Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo.
British journal of pharmacology 2009;158(1):361-71.
2007: E Ritchie; Masako Saka; Christopher MacKenzie; Robert M Drummond; C Wheeler-Jones; Toru Kanke; Robin Plevin
Cytokine upregulation of proteinase-activated-receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells.
British journal of pharmacology 2007;150(8):1044-54.
2006: Atsufumi Kawabata; Naoyuki Kawao; Tomoko Kitano; Maho Matsunami; Reiko Satoh; Tsuyoshi Ishiki; Takashi Masuko; Toru Kanke; Naohiro Saito
Colonic hyperalgesia triggered by proteinase-activated receptor-2 in mice: involvement of endogenous bradykinin.
Neuroscience letters 2006;402(1-2):167-72.
2006: Atsufumi Kawabata; Maho Matsunami; Masahiro Tsutsumi; Tsuyoshi Ishiki; Osamu Fukushima; Fumiko Sekiguchi; Naoyuki Kawao; Takeshi Minami; Toru Kanke; Naohiro Saito
Suppression of pancreatitis-related allodynia/hyperalgesia by proteinase-activated receptor-2 in mice.
British journal of pharmacology 2006;148(1):54-60.
2006: Fumiko Sekiguchi; Naomi Hasegawa; Keiko Inoshita; Daiki Yonezawa; Naoki Inoi; Toru Kanke; Naohiro Saito; Atsufumi Kawabata
Mechanisms for modulation of mouse gastrointestinal motility by proteinase-activated receptor (PAR)-1 and -2 in vitro.
Life sciences 2006;78(9):950-7.
2005: Scott R Macfarlane; Callum Sloss; Pamela Cameron; Toru Kanke; Roderick C McKenzie; Robin Plevin
The role of intracellular Ca2+ in the regulation of proteinase-activated receptor-2 mediated nuclear factor kappa B signalling in keratinocytes.
British journal of pharmacology 2005;145(4):535-44.
2005: Toshiaki Takizawa; Masaki Tamiya; Takuya Hara; Jiro Matsumoto; Naohiro Saito; Toru Kanke; Junichi Kawagoe; Yukio Hattori
Abrogation of bronchial eosinophilic inflammation and attenuated eotaxin content in protease-activated receptor 2-deficient mice.
Journal of pharmacological sciences 2005;98(1):99-102.
2005: Toru Kanke; Hiroyuki Ishiwata; Mototsugu Kabeya; Masako Saka; Takeshi Doi; Yukio Hattori; Atsufumi Kawabata; Robin Plevin
Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2.
British journal of pharmacology 2005;145(2):255-63.
2005: Atsufumi Kawabata; Yuko Oono; Daiki Yonezawa; Kaori Hiramatsu; Naoki Inoi; Fumiko Sekiguchi; Masami Honjo; Michiko Hirofuchi; Toru Kanke; Hiroyuki Ishiwata
2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice.
British journal of pharmacology 2005;144(2):212-9.
2005: Toru Kanke; Toshiaki Takizawa; Mototsugu Kabeya; Atsufumi Kawabata
Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2 as a potential therapeutic target.
Journal of pharmacological sciences 2005;97(1):38-42.
2004: Atsufumi Kawabata; Satoko Kubo; Tsuyoshi Ishiki; Naoyuki Kawao; Fumiko Sekiguchi; Ryotaro Kuroda; Morley D Hollenberg; Toru Kanke; Naohiro Saito
Proteinase-activated receptor-2-mediated relaxation in mouse tracheal and bronchial smooth muscle: signal transduction mechanisms and distinct agonist sensitivity.
The Journal of pharmacology and experimental therapeutics 2004;311(1):402-10.
2004: Hamid Reza Kazerani; Robin Plevin; Junichi Kawagoe; Toru Kanke; Brian L Furman
Lack of effect of proteinase-activated receptor-2 (PAR-2) deletion on the pathophysiological changes produced by lipopolysaccharide in the mouse: comparison with dexamethasone.
The Journal of pharmacy and pharmacology 2004;56(8):1015-20.
2004: Atsufumi Kawabata; Toru Kanke; Daiki Yonezawa; Tsuyoshi Ishiki; Masako Saka; Mototsugu Kabeya; Fumiko Sekiguchi; Satoko Kubo; Ryotaro Kuroda; Masahiro Iwaki; Kousaku Katsura; Robin Plevin
Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo.
The Journal of pharmacology and experimental therapeutics 2004;309(3):1098-107.
2004: Michael J Seatter; Robert M Drummond; Toru Kanke; Scott R Macfarlane; Morley D Hollenberg; Robin Plevin
The role of the C-terminal tail in protease-activated receptor-2-mediated Ca2+ signalling, proline-rich tyrosine kinase-2 activation, and mitogen-activated protein kinase activity.
Cellular signalling 2004;16(1):21-9.
2003: William R Ferrell; John C Lockhart; Elizabeth Kelso; Lynette Dunning; Robin Plevin; Stephen E Meek; Andrew J H Smith; Gary D Hunter; John S McLean; Frances McGarry; Robert Ramage; Lu Jiang; Toru Kanke; Junichi Kawagoe
Essential role for proteinase-activated receptor-2 in arthritis.
The Journal of clinical investigation 2003;111(1):35-41.
2002: Junichi Kawagoe; Toshiaki Takizawa; Jiro Matsumoto; Masaki Tamiya; Stephen E Meek; Andrew J H Smith; Gary D Hunter; Robin Plevin; Naohiro Saito; Toru Kanke; Mikio Fujii; Yasushi Wada
Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear.
Japanese journal of pharmacology 2002;88(1):77-84.
2001: Toru Kanke; Scott R Macfarlane; Michael J Seatter; E Davenport; Andrew Paul; R C McKenzie; Robin Plevin
Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory kappa B kinases in NCTC 2544 keratinocytes.
The Journal of biological chemistry 2001;276(34):31657-66.
2001: Scott R Macfarlane; Michael J Seatter; Toru Kanke; Gary D Hunter; Robin Plevin
Proteinase-activated receptors.
Pharmacological reviews 2001;53(2):245-82.
2001: Toshiaki Takizawa; Jiro Matsumoto; T Tohma; Toru Kanke; Y Wada; M Nagao; N Inagaki; H Nagai; M Q Zhang; H Timmerman
VUF-K-8788, a periphery-selective histamine H1 antagonist with anti-pruritic activities.
Japanese journal of pharmacology 2001;86(1):55-64.